FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208741678> ?p ?o ?g. }

• W3208741678 endingPage "5472" @default.
• W3208741678 startingPage "5472" @default.
• W3208741678 abstract "The care of metastatic colorectal cancers is based on combination chemotherapies including 5-fluorouracil, oxaliplatin, irinotecan, and monoclonal antibodies targeting the epidermal growth factor receptor or vascular endothelial growth factor. The regimen is determined based on the patient's molecular biology and general condition. Irinotecan bifractionation showed efficacy in chemorefractory patients in a previous study, FOLFIRI-3, but a desynchronized triplet has never been tested. The aim of bFOLFIRINOX-3 is to determine the safety, tolerance, and efficacy of a new regimen (FOLFIRINOX-3 bevacizumab) in chemorefractory patients. The aim of this study was to evaluate the safety and efficacy of FOLFIRINOX-3 bevacizumab in chemorefractory metastatic colorectal cancer (mCRC). A standard phase I, 3 + 3 design study was performed. The standard protocol comprised simplified FOLFOX 4 (folinic acid 400 mg/m2), 5-fluorouracil (a 400 mg/m2 bolus followed by 2400 mg/m2 for 46 h), oxaliplatin (85 mg/m2) and irinotecan (administered before and after 5-fluorouracil infusion), plus bevacizumab (5 mg/kg). In a 3 + 3 design, three different doses of irinotecan were tested: 60, 70 and 90 mg/m2. The primary endpoint was the maximum tolerable dose (MTD) of irinotecan. The secondary endpoints included the objective response (at 8 and 16 weeks) according to the RECIST 1.1 criteria and progression free survival. Thirteen patients were enrolled, and twelve patients were finally evaluated for dose-limiting toxicity (DLT). The dose level defined was 70 mg/m2 irinotecan. A total of three DLTs were observed (grade 3 diarrhea): two DLTs at the 90 mg/m2 dose level and one at the 70 mg/m2 dose level. The most frequently described adverse events were asthenia (93%), diarrhea (77%), nausea (62%) and peripheral sensory neuropathy (46%). The most frequent biological event was thrombopenia (54%). Regarding efficacy, among the 11 evaluable patients, no progression was observed at 8 weeks, and the partial response rate was 18.2%. At 16 weeks, a partial response rate of 27.3% was observed, and five patients had a stable disease. The new regimen of bFOLFIRINOX-3 with irinotecan at 70 mg/m2 was well tolerated. In chemorefractory patients, this protocol shows a high response rate." @default.
• W3208741678 created "2021-11-08" @default.
• W3208741678 creator A5002712627 @default.
• W3208741678 creator A5009612396 @default.
• W3208741678 creator A5016814827 @default.
• W3208741678 creator A5020083980 @default.
• W3208741678 creator A5043463827 @default.
• W3208741678 creator A5053571734 @default.
• W3208741678 creator A5062822105 @default.
• W3208741678 creator A5073954292 @default.
• W3208741678 creator A5078065507 @default.
• W3208741678 creator A5086294065 @default.
• W3208741678 date "2021-10-30" @default.
• W3208741678 modified "2023-10-16" @default.
• W3208741678 title "Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer" @default.
• W3208741678 cites W1503773808 @default.
• W3208741678 cites W1928747779 @default.
• W3208741678 cites W1975108860 @default.
• W3208741678 cites W2008336143 @default.
• W3208741678 cites W2012846370 @default.
• W3208741678 cites W2019990270 @default.
• W3208741678 cites W2020830322 @default.
• W3208741678 cites W2024734991 @default.
• W3208741678 cites W2032188922 @default.
• W3208741678 cites W2054660661 @default.
• W3208741678 cites W2057156320 @default.
• W3208741678 cites W2064270435 @default.
• W3208741678 cites W2085633477 @default.
• W3208741678 cites W2095201384 @default.
• W3208741678 cites W2097121246 @default.
• W3208741678 cites W2103789431 @default.
• W3208741678 cites W2106845199 @default.
• W3208741678 cites W2109498035 @default.
• W3208741678 cites W2129998117 @default.
• W3208741678 cites W2133399075 @default.
• W3208741678 cites W2139168548 @default.
• W3208741678 cites W2143743735 @default.
• W3208741678 cites W2147834058 @default.
• W3208741678 cites W2157769714 @default.
• W3208741678 cites W2261454441 @default.
• W3208741678 cites W242040007 @default.
• W3208741678 cites W2531140887 @default.
• W3208741678 cites W2562750116 @default.
• W3208741678 cites W2596517442 @default.
• W3208741678 cites W2604405550 @default.
• W3208741678 cites W2774682757 @default.
• W3208741678 cites W2783686102 @default.
• W3208741678 cites W2801603532 @default.
• W3208741678 cites W2892357948 @default.
• W3208741678 cites W2935149672 @default.
• W3208741678 cites W3009963727 @default.
• W3208741678 cites W3044774569 @default.
• W3208741678 cites W3092192928 @default.
• W3208741678 cites W3135260177 @default.
• W3208741678 doi "https://doi.org/10.3390/cancers13215472" @default.
• W3208741678 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8582415" @default.
• W3208741678 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34771635" @default.
• W3208741678 hasPublicationYear "2021" @default.
• W3208741678 type Work @default.
• W3208741678 sameAs 3208741678 @default.
• W3208741678 citedByCount "0" @default.
• W3208741678 crossrefType "journal-article" @default.
• W3208741678 hasAuthorship W3208741678A5002712627 @default.
• W3208741678 hasAuthorship W3208741678A5009612396 @default.
• W3208741678 hasAuthorship W3208741678A5016814827 @default.
• W3208741678 hasAuthorship W3208741678A5020083980 @default.
• W3208741678 hasAuthorship W3208741678A5043463827 @default.
• W3208741678 hasAuthorship W3208741678A5053571734 @default.
• W3208741678 hasAuthorship W3208741678A5062822105 @default.
• W3208741678 hasAuthorship W3208741678A5073954292 @default.
• W3208741678 hasAuthorship W3208741678A5078065507 @default.
• W3208741678 hasAuthorship W3208741678A5086294065 @default.
• W3208741678 hasBestOaLocation W32087416781 @default.
• W3208741678 hasConcept C121608353 @default.
• W3208741678 hasConcept C126322002 @default.
• W3208741678 hasConcept C143998085 @default.
• W3208741678 hasConcept C203092338 @default.
• W3208741678 hasConcept C2776694085 @default.
• W3208741678 hasConcept C2776705615 @default.
• W3208741678 hasConcept C2777802072 @default.
• W3208741678 hasConcept C2778260052 @default.
• W3208741678 hasConcept C2778496288 @default.
• W3208741678 hasConcept C2779804826 @default.
• W3208741678 hasConcept C2780259306 @default.
• W3208741678 hasConcept C2780456651 @default.
• W3208741678 hasConcept C2780962732 @default.
• W3208741678 hasConcept C2781413609 @default.
• W3208741678 hasConcept C526805850 @default.
• W3208741678 hasConcept C535046627 @default.
• W3208741678 hasConcept C71924100 @default.
• W3208741678 hasConcept C98274493 @default.
• W3208741678 hasConceptScore W3208741678C121608353 @default.
• W3208741678 hasConceptScore W3208741678C126322002 @default.
• W3208741678 hasConceptScore W3208741678C143998085 @default.
• W3208741678 hasConceptScore W3208741678C203092338 @default.
• W3208741678 hasConceptScore W3208741678C2776694085 @default.
• W3208741678 hasConceptScore W3208741678C2776705615 @default.
• W3208741678 hasConceptScore W3208741678C2777802072 @default.

• next